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Abstract
Backround: Non-alcoholic fatty liver disease (NAFLD) comprises non-progressive steatosis and non-alcoholic
steatohepatitis (NASH), the latter of which may cause cirrhosis and hepatocellular carcinoma (HCC). As NAFLD
detection is imperative for the prevention of its complications, we evaluated whether a combination of
blood-based biomarkers and anthropometric parameters can be used to predict NAFLD among overweight
and obese adults.
Methods: 143 overweight or obese non-smokers free of diabetes (50% women, age: 35–65 years) were
recruited. Anthropometric indices and routine biomarkers of metabolism and liver function were measured to
predict magnetic resonance (MR) - derived NAFLD by multivariable logistic regression models. In addition, we
evaluated to which degree the use of more novel biomarkers (adiponectin, leptin, resistin, C-reactive protein,
TNF-α, IL-6, IL-8 and interferon-γ) could improve prediction models.
Results: NAFLD was best predicted by a combination of age, sex, waist circumference, ALT, HbA1c, and
HOMA-IR at an area under the receiver operating characteristic curve (AUROC) of 0.87 (95% CI: 0.81, 0.93)
before and 0.85 (95% CI: 0.78, 0.91) after internal bootstrap validation. The use of additional biomarkers of
inflammation and metabolism did not improve NAFLD prediction. Previously published indices predicted
NAFLD at AUROCs between 0.71 and 0.82.
Conclusions: The AUROC of > 0.8 obtained by our regression model suggests the feasibility of a non-invasive
detection of NAFLD by anthropometry and circulating biomarkers, even though further increments in the
capacity of prediction models may be needed before NAFLD indices can be applied in routine clinical
practice.
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Backround
Non-alcoholic fatty liver disease (NAFLD), i.e. the
accumulation of liver fat in individuals without excessive
alcohol consumption, use of steatogenic medication or
strong genetic predisposition, is highly prevalent in
many areas of the world [1, 2]. For example, representa-
tive data from the United States indicate that 19% of
Americans may have NAFLD, and similar prevalence
rates have been reported from several regions in Asia
[1, 3]. Considering the strong positive association
between obesity and NAFLD, it can be expected that
the incidence of NAFLD will rise with increasing
obesity rates [1, 4].
NAFLD comprises non-progressive steatosis and
non-alcoholic steatohepatitis (NASH), the latter of which
may cause cirrhosis and hepatocellular carcinoma
(HCC). Moreover, NAFLD is closely linked to subclinical
inflammation and insulin resistance, and has been con-
sidered as the hepatic manifestation of the metabolic
syndrome [1, 2]. In fact, it has been proposed that
NAFLD may be a major risk factor not only for cirrhosis
and HCC, but also cardiovascular disease (CVD) and
extra-hepatic cancers driven by an unfavorable metabolic
risk profile [4, 5].
Given the high prevalence of NAFLD and its pos-
sible severe health consequences, its detection before
progression into steatohepatitis, advanced fibrosis and
cirrhosis is imperative, particularly because steatosis
alone is rapidly reversible through lifestyle modifica-
tion and particularly through weight loss [6, 7]. At
the same time, routine detection of NAFLD based on
liver biopsy, sonography and imaging may not be
feasible with respect to health care expenditures and
biopsy-related risks [8]. Thus, we tested the perform-
ance of published algorithms based on combinations
of anthropometric indices and routine blood bio-
markers [9–13] in the prediction of MRI-derived liver
fat content and NAFLD. Analyses were carried out in a
sample of overweight and obese non-diabetics, i.e. a po-
tentially ideal target population for NAFLD prevention.
Moreover, we examined if additional biomarkers that have
been proposed in the literature may improve the predic-
tion of liver fat content and NAFLD. Our goal was to as-
sess whether combinations of anthropometric parameters
and circulating biomarkers can serve as an efficient
pre-screening tool for the detection of NAFLD and steato-
hepatitis in primary care, upstream of sonography-, im-
aging-, and biopsy-based diagnostic tests.
Methods
Study population
We evaluated baseline data of the HELENA Trial, a
randomized dietary intervention study that has been
described in detail elsewhere [14]. In brief, 150
non-diabetic overweight and obese non-smokers (50%
females) aged 35–65 years entered the study between
May 2015 and May 2016. Participants were randomly
assigned to three groups (intermittent calorie restric-
tion, continuous calorie restriction, control group) for
a 12-week intervention phase, a 12-week follow-up
phase and a 26 week follow-up phase. The main ob-
jective of the trial was to evaluate whether intermit-
tent calorie restriction has stronger effects on
metabolic parameters, body composition, and psycho-
social factors than continuous calorie restriction.
At screening, study physicians carried out a general
medical assessment including anthropometric measure-
ments and a blood draw. The following exclusion cri-
teria were applied: Prevalent diabetes mellitus or
HbA1c levels ≥6.5% or fasting plasma glucose levels >
126 mg/dl; known liver dysfunction or increased GGT
(women: > 60 U/l; men: > 80 U/l), AST (> 40 U/l; >
50 U/l), or ALT (> 50 U/l; > 65 U/l) levels; known kid-
ney dysfunction or increased urea (> 50 mg/dl; >
50 mg/dl), uric acid (> 8 mg/dl; > 9 mg/dl) or creatinine
(> 1 mg/dl, > 1.3 mg/dl), known thyroid dysfunction or
increased (> 4.4 mU/l; > 4.4 mU/l) or decreased (<
0.36 mU/l; < 0.36 mU/l) thyroid-stimulating hormone
(TSH) levels; history of cancer within the past ten
years; history of eating disorders (e.g. bulimia,
binge-eating); severe bleeding tendency; use of medica-
tion for immunosuppression or modulation of fat me-
tabolism; participation in an intervention study within
the past three months; use of hormone replacement
therapy; pregnancy or breastfeeding within the past
12 months. Further exclusion criteria covered typical
MRI-contraindications (i.e., claustrophobia, cardiac
pacemakers or defibrillators, non-removable electronic
implants or devices, non 1.5 Tesla-MRI approved med-
ical foreign bodies, implants and orthopedic foreign
bodies, joint end prostheses, or other metallic foreign
bodies). Alcohol consumption was assessed by 7-day
dietary records, which were analyzed by PRODI 6.3
(Nutri-Science GmbH, Hausach, Germany).
The study was carried out at the German Cancer
Research Center (DKFZ), Heidelberg, Germany and
the Heidelberg University Hospital (imaging
component, see below). It was registered at Clinical-
Trials.gov under NCT02449148. The guidelines of the
Helsinki Declaration were applied and the study was
approved by the Ethics Committee of the Heidelberg
University Hospital (Heidelberg, Germany). All partic-
ipants provided written informed consent.
Laboratory methods
Clinical biochemistry markers (ALT, AST, GGT, ALP,
HDL-cholesterol, total cholesterol, triglycerides, fasting
glucose, HbA1c, albumin, bilirubin, ferritin, transferrin,
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total iron binding capacity) were measured directly after
blood draw at the Central Laboratory, Heidelberg Uni-
versity Hospital by routine assays. Remaining samples
were processed into EDTA-plasma, serum and buffy
coat, and frozen at − 80 °C. Plasma levels of adipo-
nectin, leptin, resistin, insulin, C-reactive protein
(CRP), tumor necrosis factor-α (TNF-α), interleukin-6
(IL-6), interleukin-8 (IL-8) and interferon-γ (IFN-γ)
were measured in the laboratory of the Division of
Cancer Epidemiology at DKFZ. A single aliquot was
thawed immediately prior to the analyses in January
2017 without previous or further freeze thaw cycles.
All analytes were measured by electrochemilumines-
cence immunoassays (ECLIA) on the “Quickplex SQ
120” instrument from Meso Scale Discoveries (MSD,
Maryland, USA), using singleplex (insulin, leptin, CRP,
IL-8, resistin, and adiponectin) and multiplex (TNF-α,
IL-6, and IFN-γ) kits from MSD.
Imaging
Liver fat content was measured using a multi-echo
GRE technique [15, 16] (Siemens LiverLab, Siemens
Healthcare, Erlangen, Germany) during a 15 min
MRI examination at the Department for Diagnostic
and Interventional Radiology, University Hospital
Heidelberg. A 1.5 Tesla MRI scanner with a 70 cm
bore design (MAGNETOM Aera; Siemens Health-
care, Erlangen, Germany) was used. Hardware,
MR-protocol and software remained constant be-
tween all MRI-scans. Details on the protocol have
previously been described [14, 15].
Imaging data on liver fat content was evaluated on
a post-processing software (OsiriX, Pixmeo SARL,
Bernex, Switzerland) manually by one reader (T.N.)
using the proton density fat fraction (PDFF) map,
based on mean counts from three identical regions of
interest (ROI, each area 4.00cm2) positioned dorsally,
anterior-medially and anterior-laterally of the right
liver lobe at a level immediate cranial of the liver
hilum, with the unit of one gray value corresponding
to a fat content of 0.1% per voxel [16] (see Fig. 1).
For the ROI placement, larger vessels and connective
tissue was avoided. ROI-data were exported using a
XML-format and could be accessed for further statis-
tical analysis. Results were validated by a second
reader (J.N.). Intra- and Inter-rater coefficients of cor-
relation were 0.99 and 0.99, respectively, indicating
excellent reliability of our liver fat quantification.
Statistical analyses
Characteristics of the study population are shown as
arithmetic mean values (continuous variables) and
proportions (categorical variables). To analyze the
correlations between anthropometric parameters,
blood biochemistry markers, and liver fat content,
Spearman’s coefficients were calculated. Moreover,
multivariable linear regression analyses were used to
establish a prediction model for liver fat content on
the continuous scale. Predictors of liver fat content
were selected by backward elimination at a p-value
threshold of 0.05 based on 100 bootstrap samples en-
tering the biomarkers described above and all an-
thropometric parameters (height, weight, BMI, waist
circumference and hip circumference) together into
the model. Predictors were chosen in case of signifi-
cant associations in two thirds of the bootstrapped
multivariable regression analyses. Age and sex were
forced into the multivariable model.
For the prediction of NAFLD as a dichotomous
outcome, we classified liver fat values > 5.56% as in-
dicative of NAFLD, as proposed by Szczepaniak et
al. [17]. Again, backward elimination at a p-value
threshold of 0.05 based was applied to determine the
final set of predictors, this time using multivariable
logistic regression models, again forcing age and sex
into the models, and entering all available bio-
markers and anthropometric parameters. The pre-
dictive power of the final combination of variables
was evaluated by areas under the receiver-operating
characteristic curves (AUROC). For internal valid-
ation, logistic regression analyses were corrected for
optimism using average beta estimates from 100
bootstraps.
In addition to our own prediction models, we tested
the following four published algorithms to predict
NAFLD:
Fig. 1 MR-image of liver with positioning of three identical
regions of interest in liver segment 4,7 and 8 using the proton
density fat fraction (PDFF) map, area of each ROI 4.00 cm2, with
the unit of one gray value corresponding to a fat content of
0.1% per voxel
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a) NAFLD liver fat score [9]:
b) Framingham Steatosis Index (FSI) [10]:
c) The Hepatic Steatosis Index (HSI) [11]:
d) The Fatty Liver Index (FLI) [12]:
We further applied the following formula developed
by Kotronen et al. [9] to predict liver fat content (%):
Results
Characteristics of the study population
Out of the 150 participants in the HELENA-Trial, 145
gave written informed consent for the MRI examination.
One stopped the MRI examination due to claustropho-
bia, and there was a technical failure regarding liver fat
quantification in another case. Thus, liver fat values were
available for 143 individuals with a mean age of 50.1 ±
8.1 years, and a mean BMI of 31.4 ± 3.7 (see Table 1).
Participants showed an average liver fat content of 7.7%,
and the prevalence of NAFLD was 52.5% (see Table 2).
The majority of the study participants had liver fat con-
tents below 15%, and only one participant had a liver fat
content > 30% (see Additional file 1: Figure S1).
Correlates of liver fat
Correlations between liver fat content (%) and the
following parameters were observed at a Spearman’s
|ρ| > 0.3 and p-values < 0.001: BMI (0.33), waist cir-
cumference (0.52), ALT (0.56), AST/ALT ratio (− 0.54),
HDL (− 0.36), triglycerides (0.33), ferritin (0.32),
HbA1c (0.31), Insulin (0.55), and HOMA-IR (0.56)
NAFLD liver fat score ¼ −2:89þ 1:18 metabolic syndrome yes ¼ 1; no ¼ 0ð Þ
þ 0:45 type 2 diabetes yes ¼ 1; no ¼ 0ð Þ þ 0:15 fS−insulin mU=Lð Þ
þ 0:04 fS−AST U=Lð Þ−0:94 AST=ALT
FSI ¼ −7:981þ 0:011 age yearsð Þ  0:146 sex female ¼ 1;male ¼ 0ð Þ þ 0:173 BMI kg=m2 
þ 0:007 triglycerides mg=dLð Þ þ 0:593 hypertension yes ¼ 1;no ¼ 0ð Þ þ 0:789 diabetes yes ¼ 1;no ¼ 0ð Þ
þ 1:1 ALT=AST ratio≥1:33 yes ¼ 1; no ¼ 0ð Þ
HSI ¼ 8 ALT=AST ratioþ BMI þ2; if DM;þ2; if femaleð Þ
FLI ¼ e0:953loge triglyceridesð Þþ0:139BMIþ0:718loge ggtð Þþ0:053waist circumference−15:745
 
=
1þ e0:953loge triglyceridesð Þþ0:139BMIþ0:718loge ggtð Þþ0:053waist circumference−15:745
 
100
Liver fat %ð Þ ¼ 10ð−0:805þ0:282metabolic syndrome yes¼1;no¼0ð Þþ0:078type 2 diabetes yes¼1;no¼0ð Þþ0:525 LOGðfS−insulin mU=Lð Þþ0:521LOGðfS−AST U=Lð Þ−0:454LOG AST=ALTð Þ
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(see Additional file 1: Figure S2). By contrast, there
was no significant correlation between self-reported
alcohol intake and liver fat content (ρ = 0.08).
After backward selection, waist, ALT, GGT, HbA1c, in-
sulin, and creatinine were significantly associated with
liver fat content in the multivariable linear regression
model at p-values < 0.05. The overall R2 of the model
after internal bootstrap validation was 53.9%. The stron-
gest predictor of liver fat content was ALT, with a
semi-partial R2 of 30.1%, followed by HbA1c (10.6%),
and GGT (6.2%) (Table 3). None of the other parameters
explained more than 5% of the variance in liver fat con-
tent. Applying the score developed by Kotronen et al. [9]
to predict liver fat content our multivariable linear re-
gression analysis revealed a model R2 of 41.4%.
NAFLD prediction models
Associations between individual predictors and the odds
ratio of NAFLD are shown in Additional file 1: Table S1.
The strongest associations were observed for ALT,
HOMA-IR, Insulin, and waist circumference, with areas
under the ROC curve of 0.78, 0.76, 0.76, and 0.75. Our
final multivariable logistic regression model to predict
NAFLD included age, sex, waist circumference, ALT,
HbA1c, and HOMA-IR. The area under the ROC curve
was 0.87 (95% CI: 0.81, 0.93) before and 0.85 (95% CI:
0.78, 0.91) after internal bootstrap validation (see Fig. 2).
At a sensitivity of 100% and a specificity of 0% (no false
negatives), our validated prediction model would have
revealed a wrong “diagnosis” of NAFLD among 47.6% of
the participants (false positives). At 95% sensitivity, our
model showed 33.8% specificity, with 14.8% false nega-
tives and 38.8% false positives. In turn, a specificity of
Table 1 Characteristics of the study population (n = 143)
General characteristics
Age 50.1 ± 8.1
Women (%) 49.7
University Degree (%) 46.1
Alcohol intake (g/d)a 11.0 ± 13.3
Anthropometry
BMI (kg/m2) 31.4 ± 3.7
Waist circumference (women) (cm) 99.5 ± 10.1
Waist circumference (men) (cm) 109.1 ± 10.6
Height (cm) 172.9 ± 9.8
Liver fat
Liver fat content (%) 7.7 ± 6.0
NAFLD (%)b 52.5
Liver function
AST (U/l) 22.9 ± 5.3
ALT (U/l) 26.7 ± 11.1
AST to ALT ratio 1.0 ± 0.3
GGT (U/l) 26.8 ± 15.8
ALP (U/l) 70.7 ± 16.9
LDH (U/l) 196.6 ± 28.7
Albumin (g/l) 43.7 ± 2.2
Bilirubin (mg/dl) 0.7 ± 0.3
Kidney function
Uric acid (mg/dl) 30.1 ± 6.8
Creatinine (mg/dl) 0.8 ± 0.1
Lipid metabolism
HDL (mg/dl) 54.0 ± 14.2
LDL (mg/dl) 125.9 ± 27.1
Triglycerides (mg/dl) 132.8 ± 80.7
Glucose metabolism
Glucose (nmol/l) 5.2 ± 0.4
HbA1c (%) 5.5 ± 0.3
Insulin (pg/ml) 6.8 ± 4.3
HOMA-IR (μU/mmol/l) 1.6 ± 1.1
Iron metabolism
Ferritin (μg/l) 148.8 ± 142.0
Iron (μmol/l) 17.9 ± 6.6
Total Iron Binding Capacity (μmol/l) 61.6 ± 7.7
Transferrin (g/l) 2.9 ± 0.4
Adipokines and cytokines
CRP (pg/ml) 3.1 ± 3.3
Adiponectin (pg/ml) 17.5 ± 11.2
Leptin (pg/ml) 8.9 ± 9.4
Resistin (pg/ml) 4.3 ± 1.8
IL-6 (pg/ml) 1.6 ± 2.0
Table 1 Characteristics of the study population (n = 143)
(Continued)
General characteristics
IL-8 (pg/ml) 11.1 ± 12.3
Interferon-γ (pg/ml) 14.8 ± 13.9
TNF-α (pg/ml) 4.5 ± 2.6
Continuous values shown as arithmetic mean ± standard deviation;
aas assessed by 7-day dietary record
bNon-alcoholic fatty liver disease (liver fat content > 5.56%)
Table 2 Proportion of individuals with NAFLDa
Overall 52.5%
Women 43.6%
Men 61.1%
BMI: 25–29.9b 35.7%
BMI: 30–34.9b 62.3%
BMI: 35–39.9b 65.4%
aNon-alcoholic fatty liver disease (liver fat content > 5.56%)
bProportions of individuals with BMI values of 25–29.9, 30–34.9, and 35–39.9
were: 39.2 (%), 42.7 (%) and 18.2 (%)
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95% was associated with a sensitivity of 53.3% (35.0%
false positives and 7.0% false negatives). According to
the Youden statistic, the optimal cut-point correspond-
ing to the maximum sum of sensitivity and specificity in
the validated model was at 0.36 (sensitivity: 69.3%, speci-
ficity: 85.3%). Of note, none of the tested biomarkers of
metabolism and inflammation (adiponectin, leptin, resis-
tin, C-reactive protein, TNF-α, IL-6, IL-8 and IFN-γ)
was significantly associated with liver fat content or
NAFLD in our regression analyses. The application of
previously published indices in our study sample re-
vealed areas under the ROC curve of 0.82 [NAFLD Liver
Fat Score by Kotronen et al. [9]], 0.74 [FSI by Long et al.
[10]], 0.71 [HSI by Lee et al. [11]], and 0.77 [FLI by
Bedogni et al. [12]] (see Table 4).
Using an alternative cut-point for NAFLD at 5% liver
fat instead of 5.56%, as proposed by some experts [18],
in sensitivity analyses yielded highly similar results, as
only two individuals with liver fat values between 5 and
5.56% had to be re-classified. The areas under the ROC
curves with our prediction formula were 0.88 (95% CI:
0.82, 0.93) before and 0.84 (95% CI: 0.78, 0.91) after
internal bootstrap validation. When we applied our for-
mula to predict NAFLD among overweight individuals
only, the area under the ROC curve upon bootstrap
validation (0.80, 95% CI: 0.68, 0.92) was slightly lower
compared than the one obtained among obese individ-
uals only (0.84, 95% CI: 0.76, 0.93).
Discussion
In the present study, we assessed anthropometric parame-
ters and blood biomarkers as potential predictors of liver
fat content and NAFLD among overweight and obese
non-diabetics. Liver fat showed the strongest correlations
with waist circumference (ρ = 0.52), ALT (ρ = 0.56), and
insulin (ρ = 0.55) as well as HOMA-IR (ρ = 0.56). A multi-
variable linear regression model based on waist, ALT,
GGT, HbA1c, insulin, and creatinine explained 54% of the
variance in liver fat content. A similar combination of
markers (age, sex, waist circumference, ALT, HbA1c, and
HOMA-IR) showed a good prediction capacity regarding
NAFLD, with an AUROC of 0.87, which was slightly at-
tenuated after internal bootstrap validation (0.85).
Several groups have established indices based on an-
thropometry and routine biomarkers for the prediction
of fatty liver disease before us, to our knowledge without
external validation [9–12]; thus, one of our goals was to
assess how existing indices perform in our study popula-
tion. The NAFLD Liver Fat Score developed by Kotronen
et al. [9], which is based on the presence of the meta-
bolic syndrome and type 2 diabetes (dichotomous vari-
ables) in addition to insulin, AST, and the AST/ALT
ratio, predicted NAFLD with an AUROC of 0.82 in our
study population, even though individuals with diabetes
Fig. 2 ROC curves for NAFLD prediction models from logistic regression analyses before (left) and after (right) internal bootstrap validation. Our
validated model has the following regression formula: NAFLD = − 22.8113 + 0.00317*Age - 0.5036*Female Sex + 0.0609*Waist (cm) + 0.1292 ALT (U/l)
+ 2.1868*HbA1c (%) + 0.8066*HOMA-IR (μU/mmol/l)
Table 3 Predictors of liver fat content (%)a
Semi-partial R2 (Type II)b p
Age < 1% 0.88
Sex 3.5% 0.03
Waist 4.9% < 0.01
ALT 30.1% < 0.01
GGT 6.2% < 0.01
HbA1c 10.6% < 0.01
Insulin 3.8% 0.02
Creatinine 3.5% 0.03
aOverall R2: 53.9%
bDo not add up to overall R2
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were excluded from our study. This is consistent with
our observation that the strongest predictors of NAFLD
are markers of liver function (AST/ALT or ALT) and in-
sulin sensitivity (insulin or HOMA-IR). Unlike in our
prediction model, waist circumference was not part of
the NAFLD Liver Fat Score. However, considering that
waist circumference is a hallmark of the metabolic syn-
drome and type 2 diabetes [19], our regression model
and the NAFLD Liver Fat Score contain highly similar
sets of predictors [9].
Our prediction models for liver fat on the continuous
scale revealed a model R2 of 53.9% when using our own
set of predictors (waist, ALT, GGT, HbA1c, insulin, and
creatinine) vs. 41.4% when using the predictors selected
by Kotronen et al. (AST, AST/ALT ratio, diabetes type 2,
metabolic syndrome, and insulin) [9]. This difference
may be due to the fact that we test a broader set of pre-
dictors for our model than Kotronen and colleagues,
who obtained an adjusted R2 of 49% in their own study.
In any case, it should be noted that either model ex-
plains only up to ~ 50% of the variance in liver fat so
that both models may only facilitate a rough projection
of true liver fat content [9].
The lack of parameters of insulin sensitivity in other
previously published indices, i.e. FLI, FSI, and HSI [10–
12] may explain why these revealed AUROCs below 0.8
in our sample. Interestingly, Bedogni et al., who devel-
oped the highly cited FLI, did find insulin levels to be a
strong predictor of fatty liver in their study, but decided
not to include insulin into the FLI, since it was not rou-
tinely measured in clinical practice [12]. The methodolo-
gies used for NAFLD assessment constitute another
major difference between previous studies and ours.
While Kotronen et al. used MRI-techniques (spectros-
copy) for quantification of liver fat content, which is
comparable with our MRI-technique [16, 20, 21], in the
other studies ultrasound or computed tomography were
used for assessing liver fat content, which are less pre-
cise compared to MRI-techniques [10–12, 22, 23].
Other than expected, none of the metabolic (adiponec-
tin, resistin, leptin) and inflammatory factors (CRP,
TNF-α, IL-6, IL-8 and IFN-γ), which have been pro-
posed as potential circulating markers of NAFLD [24,
25], were significantly associated with liver fat content
(%) and NAFLD in our study. Our analyses did not show
associations for markers of iron status, either, although
iron overload has been described as a feature of NAFLD
[18, 26]. In part, the observed lack of associations with
these blood-based biomarkers may be explained by the
fact that our study population consisted of overweight
and obese individuals who were free of diabetes and
other metabolic complications, and that alterations of
adipokine and cytokine signaling as well as iron metab-
olism may be related to the development of more ad-
vanced metabolic dysfunction. In this regard, it is
important to note that most individuals in our trial had
liver fat values below 30%.
Our study had several limitations. As stated above, we
did not have the opportunity to validate our prediction
model externally. Stratified analyses by different degrees
of overweight and obesity were restricted due to the lim-
ited sample size, and out trial did not have a follow-up
on major clinical outcomes. While our biomarker ana-
lyses covered a wide range of routine and putative novel
markers of NAFLD, we did not have the opportunity to
measure more costly non-routine parameters such as
sCD36 or procollagen III N-terminal peptide, or to use
commercial NAFLD tests based on circulating markers
[24, 25, 27]. We did not have information on genetic
markers of NAFLD [28]. However, PNPLA3 (patatin-like
phospholipasedomain-containing 3), the only more
established genetic marker of NAFLD, did not improve
NAFLD prediction in the study by Kotronen et al. [9].
Finally, as in many other studies and routine clinical
practice, we did not perform biopsies of the liver paren-
chyma, given the risk of complications so that no in-
ternal comparison between histological and MRI data
was possible. Thus, and because the vast majority of our
Table 4 Areas under the receiver operator characteristic curves (AUROC) for the prediction of NAFLD derived from different models
in the HELENA-Trial (n = 143)
Included Predictors Reference AUROC
NAFLD liver fat score Metabolic syndrome, Diabetes, AST, AST/ALT ratio, Insulin Kotronen et al. 2009 [9] 0.82 (0.75–0.89)
Framingham Steatosis Index (FSI) Age, Sex,
BMI, Hypertension, Diabetes, ALT/AST ratio, Triglycerides
Long et al. 2016 [10] 0.74 (0.65–0.82)
The Hepatic Steatosis Index (HSI) Sex,
BMI, Diabetes,
ALT/AST ratio
Lee et al. 2009 [11] 0.71 (0.63–0.80)
The Fatty Liver Index (FLI) BMI, Waist circumference,
GGT, Trygylcerides
Bedogni et al. 2006 [12] 0.77 (0.70–0.85)
Helena-Trial Index Age, Sex,
Waist circumference,
ALT, HbA1c, HOMA-IR
Present Study 0.85 (0.78, 0.91)a
aafter internal bootstrap validation
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population had liver fat values below 30%, we could not
assess different grades of steatosis. Nevertheless,
MRI-techniques are a proven exact method for liver fat
content assessment and are superior to ultrasound de-
rived diagnosis of steatosis [18].
Conclusions
In summary, NAFLD was predicted by a combination of
waist circumference, ALT, HbA1c, and HOMA-IR at an
AUROC of 0.85 (after internal validation) among over-
weight and obese adults, free of manifest metabolic com-
plications. This result appears highly promising with
respect to clinical routine care considering that the used
predictors are easily available without relevant health
care expenditures. Considering that all other potential
first-line screening tools have specific disadvantages re-
lated to costs, patient burden, and sensitivity [29–32],
our prediction model may be an interesting tool to iden-
tify persons at risk of NAFLD-induced steatohepatitis,
fibrosis and cirrhosis, who could be pre-screened for
further diagnostic tests by sonography, imaging or liver
biopsy. Nevertheless, it has to be acknowledged that
external validation of our prediction model is needed,
and that the previously existing NAFLD prediction algo-
rithm that performed best in our collective showed an
AUROC of 0.82, which is very reasonable but not excel-
lent. It remains to be seen whether novel markers be-
yond those we tested in the present study may further
increase sensitivity and specificity of NAFLD indices, so
as to justify a wider use in first-line screening.
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